AU765218B2 - A novel chimeric protein for prevention and treatment of HIV infection - Google Patents

A novel chimeric protein for prevention and treatment of HIV infection Download PDF

Info

Publication number
AU765218B2
AU765218B2 AU38896/00A AU3889600A AU765218B2 AU 765218 B2 AU765218 B2 AU 765218B2 AU 38896/00 A AU38896/00 A AU 38896/00A AU 3889600 A AU3889600 A AU 3889600A AU 765218 B2 AU765218 B2 AU 765218B2
Authority
AU
Australia
Prior art keywords
protein
binding
protein according
binding domain
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38896/00A
Other languages
English (en)
Other versions
AU3889600A (en
Inventor
Edward A. Berger
Christie M. Del Castillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, US Department of Health and Human Services filed Critical National Institutes of Health NIH
Publication of AU3889600A publication Critical patent/AU3889600A/en
Application granted granted Critical
Publication of AU765218B2 publication Critical patent/AU765218B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU38896/00A 1999-03-16 2000-03-16 A novel chimeric protein for prevention and treatment of HIV infection Ceased AU765218B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12468199P 1999-03-16 1999-03-16
US60/124681 1999-03-16
PCT/US2000/006946 WO2000055207A1 (en) 1999-03-16 2000-03-16 A novel chimeric protein for prevention and treatment of hiv infection

Publications (2)

Publication Number Publication Date
AU3889600A AU3889600A (en) 2000-10-04
AU765218B2 true AU765218B2 (en) 2003-09-11

Family

ID=22416252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38896/00A Ceased AU765218B2 (en) 1999-03-16 2000-03-16 A novel chimeric protein for prevention and treatment of HIV infection

Country Status (8)

Country Link
EP (1) EP1161455B1 (https=)
JP (1) JP2002538814A (https=)
AT (1) ATE407146T1 (https=)
AU (1) AU765218B2 (https=)
CA (1) CA2361292C (https=)
DE (1) DE60040136D1 (https=)
ES (1) ES2313886T3 (https=)
WO (1) WO2000055207A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
IL141023A0 (en) * 2001-01-22 2002-02-10 Gavish Galilee Bio Appl Ltd Recombinant polypeptides for effective hiv neutralization
US20030082630A1 (en) * 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2003040311A2 (en) 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
WO2003095492A1 (en) 2002-05-06 2003-11-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2484930A1 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
ES2319838B1 (es) * 2006-09-29 2010-02-11 Consejo Superior Investig. Cientificas Uso de inhibidores de la actividad de la proteina filamina a, para la elaboracion de composiciones farmaceuticas, compuestos inhibidores de dicha actividad, composiciones farmaceuticas y sus aplicaciones terapeuticas y procedimiento identificacion de dichos compuestos inhibidores.
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
EP3303373B1 (en) * 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP4004049A1 (en) * 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047318A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047318A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE V 280 (1998) P 1833-24 *
SCIENCE V 280 (1998) P 1949-53 *

Also Published As

Publication number Publication date
ES2313886T3 (es) 2009-03-16
EP1161455B1 (en) 2008-09-03
CA2361292C (en) 2012-05-29
CA2361292A1 (en) 2000-09-21
ATE407146T1 (de) 2008-09-15
DE60040136D1 (de) 2008-10-16
WO2000055207A1 (en) 2000-09-21
EP1161455A1 (en) 2001-12-12
JP2002538814A (ja) 2002-11-19
AU3889600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
US20130189264A1 (en) A novel chimeric protein for prevention and treatment of hiv infection
Boyd et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development
US10246505B2 (en) Chimeric antigen receptors to control HIV infection
JP4642035B2 (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
US5961976A (en) Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
JP3808553B2 (ja) Ｃｔｌａ４変異体分子およびそれの使用
AU765218B2 (en) A novel chimeric protein for prevention and treatment of HIV infection
WO1993008829A1 (en) Compositions that mediate killing of hiv-infected cells
JPH02501192A (ja) 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
JPH03504234A (ja) 可溶性ヒトｃｄ４断片及びその使用
US6121021A (en) Constitutive expression of non-infectious HIV-like particles
EP0910659B1 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
CZ239694A3 (en) Recombinant human antibody against hiv, cassette for expression, host cell and a pharmaceutical preparation against hiv
WO2003040311A2 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
CN114907490B (zh) 强效双功能hiv进入抑制剂及其应用
US20040214285A1 (en) HIV-specific fusion proteins and therapeutic and diagnostic methods for use
US20030211470A1 (en) CD4-IgG2-based salvage therapy of HIV-1 infection
JP2009082135A (ja) Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
AU6535099A (en) Multispecific chimeric receptors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)